CERo Therapeutics Holdings, Inc.

Contributing Author

Recent Articles by CERo Therapeutics Holdings, Inc.

Oct-29	CERo Therapeutics Announces Receipt of Nasdaq Panel Determination CERO GlobeNewswire
Oct-21	CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML CERO GlobeNewswire
Oct-15	CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 CERO GlobeNewswire
Oct-13	CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML CERO GlobeNewswire
Sep-22	CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort CERO GlobeNewswire
Sep-09	CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 CERO GlobeNewswire
Sep-08	CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia CERO GlobeNewswire
Sep-05	CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) CERO GlobeNewswire
Jul-31	CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 CERO GlobeNewswire
Jun-23	CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 CERO GlobeNewswire
Jun-17	CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) CERO GlobeNewswire
Jun-11	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split CERO GlobeNewswire
Jun-06	CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing CERO GlobeNewswire
Jun-02	CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 CERO GlobeNewswire
May-30	CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations CERO GlobeNewswire
May-08	CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) CERO GlobeNewswire
Apr-30	CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia CERO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.